Vimarsana
Biggest News Aggregation in the World

Page 2 - Data Presentations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Data Presentations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Data Presentations Today - Breaking & Trending Today

Imago BioSciences Reports First Quarter 2022 Financial Results and Provides Recent Business Updates - Vimarsana News

Imago BioSciences Reports First Quarter 2022 Financial Results and Provides Recent Business Updates

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Antengene Announces 2021 Full Year Financial Results and Provides Corporate Updates - Vimarsana News

Antengene Announces 2021 Full Year Financial Results and Provides Corporate Updates

/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to...

Antengene Announces 2021 Full Year Financial Results and Provides Corporate Updates - Vimarsana News

Antengene Announces 2021 Full Year Financial Results and Provides Corporate Updates

/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to...

Antengene Announces 2021 Full Year Financial Results and Provides Corporate Updates - Vimarsana News

Antengene Announces 2021 Full Year Financial Results and Provides Corporate Updates

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Antengene Announces 2021 Full Year Financial Results and Provides Corporate Updates - Vimarsana News

Antengene Announces 2021 Full Year Financial Results and Provides Corporate Updates

- XPOVIO® (selinexor) approvals received in Mainland China, Australia, South Korea and Singapore, expect Hong Kong and Taiwan in remainder of 2022. - 2021 Revenue of RMB28.8 million, Named Patient Program paving way for strong commercial launch in 2022. - Broad and deep clinical program of 18 studies, including 5 registrational studies, ongoing across multiple regions. - Strong cash,...